Alto Neuroscience (NYSE:ANRO) Research Coverage Started at Chardan Capital

Chardan Capital assumed coverage on shares of Alto Neuroscience (NYSE:ANRO) in a report published on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $15.00 price target on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Alto Neuroscience in a report on Monday, August 18th. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.80.

Alto Neuroscience Price Performance

Shares of ANRO opened at $4.09 on Monday. The firm has a market capitalization of $110.76 million, a price-to-earnings ratio of -1.71 and a beta of 2.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 18.43 and a current ratio of 18.43. Alto Neuroscience has a one year low of $1.60 and a one year high of $15.04. The stock’s fifty day moving average is $3.57 and its 200-day moving average is $2.83.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Equities analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ANRO. Bank of Montreal Can acquired a new position in Alto Neuroscience during the second quarter worth about $25,000. Ground Swell Capital LLC purchased a new position in Alto Neuroscience in the 2nd quarter worth about $27,000. Vanguard Personalized Indexing Management LLC purchased a new position in Alto Neuroscience in the 2nd quarter worth about $33,000. AlphaCore Capital LLC increased its stake in Alto Neuroscience by 100.0% in the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new position in Alto Neuroscience in the 1st quarter worth about $52,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.